{
    "2021-08-16": [
        [
            {
                "time": "",
                "original_text": "【国元医药|点评】长春高新2021年中报点评：生长激素维持高速增长，疫苗板块未来可期",
                "features": {
                    "keywords": [
                        "长春高新",
                        "生长激素",
                        "高速增长",
                        "疫苗板块",
                        "未来可期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "并购Samton加速产业布局，新纽科技缘何青睐SaaS业务？",
                "features": {
                    "keywords": [
                        "并购",
                        "Samton",
                        "产业布局",
                        "新纽科技",
                        "SaaS业务"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "软件服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}